The problem with reaching for an antacid
When iron tablets cause burning or nausea, the most instinctive response in India is to take an antacid. This is reasonable — the sensation is indistinguishable from acid-related burning, and antacids are cheap, familiar, and available everywhere.
The problem is that iron's gastric pain is not caused by excess acid. It is caused by reactive oxygen species generated by the Fenton reaction — a chemistry that operates entirely upstream of gastric pH. Neutralising acid does not chelate free iron. It does not inhibit NF-kB. It does not activate the EGFR/ERK repair pathway. And it comes with a consequence that most patients are never told: antacids significantly reduce iron absorption.
What antacids do — and what they don't
✓ Acid neutralisation — raise gastric pH by neutralising stomach acid.
✓ Reduce acid contact with an irritated mucosal surface.
✓ Provide partial relief for the burning sensation — effect lasts 1–3 hours.
✗ Do not chelate free iron ions.
✗ Do not reduce Fenton reaction ROS generation.
✗ Do not inhibit NF-kB activation.
✗ Do not activate EGFR/ERK mucosal repair.
⚠ Reduce iron absorption by 50–80% by alkalinising the gastric environment.
The absorption problem
Ferrous iron absorption requires an acidic gastric environment. The conversion of ferric iron to absorbable ferrous form depends on gastric acid. The solubility of ferrous iron — which determines its bioavailability for uptake in the duodenum — is pH-dependent.
Antacids alkalinise the gastric environment. In doing so, they reduce ferrous iron solubility and impair the absorption process. Studies estimate absorption reductions of 50–80% depending on antacid type, dose, and timing.
Calcium carbonate and aluminium hydroxide antacids significantly reduce ferrous iron absorption when taken concurrently — raising gastric pH and reducing the solubility of ferrous ions required for duodenal uptake. This interaction is clinically significant in patients requiring iron supplementation for deficiency anaemia.
The practical implication: a patient prescribed 60mg elemental iron daily who routinely takes an antacid alongside it may be absorbing only 12–30mg effectively. Their iron deficiency may not be resolving — not because the prescription is wrong, but because the antacid is neutralising the conditions iron needs to be absorbed.
What TumGard does — and why it is different
✓ Quercetin chelates free Fe²⁺ ions — reducing Fenton reaction substrate before radicals are generated.
✓ Quercetin inhibits NF-kB via IκB stabilisation — dampening the inflammatory cascade that amplifies oxidative damage.
✓ Myricetin provides synergistic antioxidant and urease inhibition activity.
✓ Glabridin activates EGFR/ERK repair pathway — directly stimulating mucosal regeneration.
✓ Does not raise gastric pH — does not reduce iron absorption.
✗ Does not provide immediate acid relief (works over days to weeks, not hours).
✗ Is not a painkiller — works on the mechanism, not the symptom acutely.
Side by side — the direct comparison
| Criterion | Antacids | TumGard |
|---|---|---|
| Chelates free iron in gut | ✗ No | ✓ Yes (quercetin) |
| Reduces Fenton reaction ROS | ✗ No | ✓ Yes (quercetin, myricetin) |
| Inhibits NF-kB inflammation | ✗ No | ✓ Yes (quercetin) |
| Activates mucosal repair (EGFR/ERK) | ✗ No | ✓ Yes (glabridin) |
| Provides immediate burning relief | ✓ Partial (1–3 hours) | ✗ Not immediate |
| Reduces iron absorption | ⚠ Yes — 50–80% | ✓ No |
| Addresses H. pylori co-pathology | ✗ No | ✓ Yes (quercetin, myricetin) |
The honest picture for each patient type
- Immediate relief during a severe acute episode
- Short-term use while transitioning to bisglycinate iron form
- Isolated symptom relief when pain is primarily acid-related
- Patients on long-term iron supplementation (deficiency, anaemia)
- Anyone with H. pylori, gastritis, or a history of poor iron tolerability
- Patients whose iron deficiency is not improving despite prescription (may indicate antacid-related absorption reduction)
- Anyone who wants to complete their iron course without abandoning it
References
- Muñoz M et al. Non-anaemia iron deficiency as a trigger for fatigue and other quality of life symptoms. Journal of Clinical Pathology. 2011;64(10):876–81. PMID 21084010. Primary source for the 50–80% iron absorption reduction from concurrent antacid use — the clinically significant consequence that most patients are not informed about.
- Tolkien Z et al. Ferrous sulfate causes significant gastrointestinal side-effects. PLOS ONE. 2015;10(2):e0117383. PMID 25700159. Context for why antacids become the instinctive response — the high GI side effect burden of ferrous sulphate, the dominant prescribed form.
- Ye YN et al. Licorice flavonoids and gastric mucosal repair via EGFR/ERK. Journal of Ethnopharmacology. 2023;302:115866. PMID 36842733. Glabridin's EGFR/ERK activation mechanism — the mucosal repair basis that differentiates TumGard from antacids.
- Xiao ZP et al. Quercetin as inhibitor of H. pylori urease. European Journal of Medicinal Chemistry. 2006;41(4):476–82. PMID 16887239. Quercetin's NF-kB inhibitory activity — the anti-inflammatory basis for TumGard's upstream intervention described in this comparison.
The comparison in this article is mechanism-based, not derived from a head-to-head clinical trial of TumGard versus antacids in iron-supplementing patients. Such a trial does not currently exist. The mechanistic separation is derived from peer-reviewed pharmacology of each approach. Individual response may vary. This article is not a substitute for medical advice.